Please Wait.....
Report
NA Antiviral Drugs Market - Industry Trends and Forecast to 2030
Market Report I 2023-05-01 I 352 Pages I Data Bridge Market Research
North America antiviral drugs market is expected to reach USD 63,215.26 million by 2030 from USD 41,359.32 million in 2022, growing with a CAGR of 5.5% during the forecast period from 2023 to 2030.
Market Segmentation:
North America Antiviral Drugs Market, By Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus (RSV), Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030.
Overview of North America Antiviral Drugs Market Dynamics :
Driver
- Rising prevalence of viral infections
Restrain
- High cost of antiviral drugs
Opportunity
- Increasing collaboration and partnership among key players
Market Players:
Some of the key market players operating in the North America antiviral drugs market are listed below:
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche Ltd
- GLAXOSMITHKLINE PLC
- Abbvie
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Aurobindo Pharma
- Dr. Reddy's Laboratories Ltd.
- Zydus Pharmaceuticals, Inc.
- Mylan Pharmaceuticals ULC
- Teva Pharmaceuticals USA, Inc.
- EMERGENT
- Sun Pharmaceutical Industries Ltd.
- Avet Pharmaceuticals Inc.
- Pfizer Inc.
- SIGA Technologies
- NAVINTA LLC.
- Macleods Pharmaceuticals Ltd.
- BioCryst Pharmaceuticals, Inc
- Hetero
TABLE OF CONTENTS
1 INTRODUCTION 119
1.1 OBJECTIVES OF THE STUDY 119
1.2 MARKET DEFINITION 119
1.3 OVERVIEW OF THE NORTH AMERICA ANTIVIRAL DRUGS MARKET 119
1.4 LIMITATIONS 121
1.5 MARKETS COVERED 121
2 MARKET SEGMENTATION 127
2.1 MARKETS COVERED 127
2.2 GEOGRAPHICAL SCOPE 128
2.3 YEARS CONSIDERED FOR THE STUDY 129
2.4 CURRENCY AND PRICING 129
2.5 DBMR TRIPOD DATA VALIDATION MODEL 130
2.6 MULTIVARIATE MODELLING 133
2.7 PRODUCT TYPE LIFELINE CURVE 133
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.9 DBMR MARKET POSITION GRID 135
2.10 MARKET TESTING TYPE COVERAGE GRID 136
2.11 VENDOR SHARE ANALYSIS 137
2.12 SECONDARY SOURCES 138
2.13 ASSUMPTIONS 138
3 EXECUTIVE SUMMARY 139
4 PREMIUM INSIGHTS 142
4.1 PORTER'S FIVE FORCES 143
4.2 PESTEL ANALYSIS 144
5 EPIDEMIOLOGY 145
6 PIPELINE ANALYSIS FOR NORTH AMERICA ANTIVIRAL DRUGS MARKET 146
7 REGULATORY FRAMEWORK 147
8 MARKET OVERVIEW 149
8.1 DRIVERS 151
8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 151
8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 151
8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 153
8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 153
8.2 RESTRAINS 154
8.2.1 HIGH COST OF ANTIVIRAL DRUGS 154
8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 154
8.3 OPPORTUNITIES 155
8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 155
8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 155
8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 156
8.4 CHALLENGES 157
8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 157
8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 158
9 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY INDICATION 159
9.1 OVERVIEW 160
9.2 INFLUENZA 163
9.2.1 NEURAMINIDASE INHIBITORS 164
9.2.1.1 OSELTAMIVIR 164
9.2.1.2 ZANAMIVIR 164
9.2.1.3 PERAMIVIR 164
9.2.1.4 LANINAMIVIR 164
9.2.2 M2 INHIBITORS 165
9.2.2.1 RIMANTADINE 165
9.2.2.2 OTHERS 165
9.2.3 RNA POLYMERASE INHIBITORS 165
9.2.3.1 FAVIPIRAVIR 165
9.2.3.2 BALOXAVIR MARBOXIL 165
9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 166
9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 167
9.3.1.1 NUCLEOSIDE (NRTIS) 167
9.3.1.1.1 LAMIVUDINE 168
9.3.1.1.2 ABACAVIR 168
9.3.1.1.3 DIDANOSINE 168
9.3.1.1.4 OTHERS 168
9.3.1.2 NONNUCLEOSIDE (NNRTIS) 168
9.3.1.2.1 EFAVIRENZ 168
9.3.1.2.2 NEVIRAPINE 168
9.3.1.2.3 DELAVIRDINE 168
9.3.1.2.4 OTHERS 169
9.3.1.3 INTEGRASE 169
9.3.1.3.1 DOLUTEGRAVIR 169
9.3.1.3.2 ELVITEGRAVIR 169
9.3.1.3.3 RALTEGRAVIR 169
9.3.1.3.4 BICTEGRAVIR 169
9.3.1.4 NUCLEOTIDE 169
9.3.1.4.1 TENOFOVIR 170
9.3.1.4.2 OTHERS 170
9.3.1.5 INTERFERONS 170
9.3.1.5.1 ALPHA 170
9.3.1.5.2 BETA 170
9.3.1.5.3 GAMMA 171
9.3.1.6 GP41 171
9.3.1.6.1 ENFUVIRTIDE 171
9.3.1.6.2 OTHERS 171
9.3.2 PROTEASE 172
9.3.2.1 ATAZANAVIR 172
9.3.2.2 DARUNAVIR 172
9.3.2.3 LOPINAVIR 172
9.3.2.4 RITONAVIR 172
9.3.2.5 SAQUINAVIR 172
9.3.2.6 INDINAVIR 172
9.3.2.7 NELFINAVIR 173
9.3.2.8 TIPRANAVIR 173
9.3.2.9 AMPRENAVIR 173
9.4 HEPATITIS C VIRUS 173
9.4.1 NS5B POLYMERASE 174
9.4.1.1 SOFOSBUVIR 174
9.4.1.2 DASABUVIR 174
9.4.2 NS3/4A PROTEASE 175
9.4.2.1 DANOPREVIR 175
9.4.2.2 GLECAPREVIR 175
9.4.2.3 GRAZOPREVIR 175
9.4.2.4 PARITAPREVIR 175
9.4.2.5 SIMEPREVIR 175
9.4.3 NS5A PHOSPHOPROTEIN 176
9.4.3.1 LEDIPASVIR 176
9.4.3.2 VELPATASVIR 176
9.4.3.3 OMBITASVIR 176
9.4.3.4 ELBASVIR 176
9.4.3.5 DACLATASVIR 176
9.4.3.6 PIBRENTASVIR 176
9.4.4 NEURAMINIDASE 177
9.4.4.1 OSELTAMIVIR 177
9.4.4.2 ZANAMIVIR 177
9.4.4.3 PERAMIVIR 177
9.4.4.4 LANINAMIVIR 177
9.4.5 RNA POLYMERASE 177
9.4.5.1 BALOXAVIR MARBOXIL 178
9.4.5.2 FAVIPIRAVIR 178
9.4.6 MATRIX PROTEIN 2 178
9.4.6.1 RIMATIDINE 178
9.4.6.2 FAVIPIRAVIR 178
9.5 HERPES SIMPLEX VIRUS 179
9.5.1 DNA POLYMERASE UL30 180
9.5.1.1 ACICLOVIR 180
9.5.1.2 FAMCICLOVIR 180
9.5.1.3 VALACICLOVIR 180
9.5.1.4 PENCICLOVIR TRIFLURIDINE 180
9.5.1.5 BRIVUDINE 180
9.5.1.6 FOSCARNET 180
9.5.1.7 IDOXURIDINE 181
9.5.2 ENVELOPE PROTEINS 181
9.5.2.1 DOCOSANOL 181
9.5.2.2 OTHERS 181
9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 181
9.6.1 GANCICLOVIR 182
9.6.2 VALGANCICLOVIR 182
9.6.3 CIDOFOVIR 182
9.6.4 FOSCARNET 182
9.6.5 FOMIVIRSEN 182
9.7 VARICELLA-ZOSTER VIRUS (VZV) 183
9.7.1 VALACICLOVIR 184
9.7.2 FAMCICLOVIR 184
9.7.3 ACICLOVIR 184
9.7.4 VIDARABINE 184
9.7.5 BRIVUDINE 184
9.8 HEPATITIS B VIRUS 184
9.8.1 ENTECAVIR 185
9.8.2 TENOFOVIR 185
9.8.3 TELBIVUDINE 185
9.8.4 TENOFOVIR ALAFENAMIDE 186
9.8.5 OTHERS 186
9.9 RESPIRATORY SYNCYTIAL VIRUS 186
9.9.1 RNA POLYMERASE 187
9.9.1.1 RIBAVIRIN 187
9.9.1.2 OTHERS 187
9.9.2 FUSION GLYCOPROTEIN 187
9.9.2.1 PALIVIZUMAB 188
9.9.2.2 OTHERS 188
9.10 CORONAVIRUS INFECTION 188
9.11 OTHERS 189
10 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 190
10.1 OVERVIEW 191
10.2 GERIATRIC 194
10.2.1 MALE 194
10.2.2 FEMALE 194
10.3 CHILD 195
10.3.1 MALE 195
10.3.2 FEMALE 196
10.4 ADULT 196
10.4.1 MALE 197
10.4.2 FEMALE 197
11 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS 198
11.1 OVERVIEW 199
11.2 ORAL 202
11.2.1 SOLID 203
11.2.1.1 TABLETS 203
11.2.1.2 CAPSULES 203
11.2.1.3 OTHERS 203
11.2.2 SEMISOLID 203
11.2.2.1 GELS 204
11.2.2.2 EMULSIONS 204
11.2.2.3 ELIXIRS 204
11.2.2.4 OTHERS 204
11.2.3 LIQUID 204
11.2.3.1 SOLUTIONS 204
11.2.3.2 SYRUPS 204
11.2.3.3 OTHERS 204
11.3 TOPICAL 205
11.3.1 SEMI-SOLID 206
11.3.1.1 CREAM 206
11.3.1.2 OINTMENT 206
11.3.1.3 GELS 206
11.3.1.4 OTHERS 206
11.3.2 LIQUID 206
11.3.2.1 SOLUTIONS 207
11.3.2.2 SUSPENSIONS 207
11.3.3 SOLID 207
11.3.3.1 POWDERS 207
11.3.3.2 SUPPOSITORIES 207
11.3.3.3 ENEMA 207
11.3.3.4 OTHERS 207
11.4 PARENTERAL 208
11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 209
11.4.1.1 SOLUTIONS 209
11.4.1.2 RECONSTITUTED/LYOPHILIZED 209
11.4.1.3 SUSPENSIONS 209
11.4.1.4 EMULSIONS 209
11.4.1.5 OTHERS 209
11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 210
11.4.3 COLLOIDAL DISPERSIONS 210
11.4.4 LONG ACTING INJECTION FORMULATION 210
12 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 211
12.1 OVERVIEW 212
12.2 GENERIC 215
12.3 BRANDED 215
13 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY END USER 216
13.1 OVERVIEW 217
13.2 HOSPITAL 220
13.3 SPECIALTY CENTERS 220
13.4 AMBULATORY CENTRES 221
13.5 CLINICS 221
13.6 HOME HEALTHCARE 221
13.7 OTHERS 222
14 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 223
14.1 OVERVIEW 224
14.2 HOSPITAL PHARMACY 227
14.3 RETAIL PHARMACY 227
14.4 ONLINE PHARMACY 228
15 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY REGION 229
15.1 NORTH AMERICA 230
15.1.1 U.S. 253
15.1.2 CANADA 272
15.1.3 MEXICO 289
16 NORTH AMERICA ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE 307
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 307
17 SWOT ANALYSIS 308
18 COMPANY PROFILE 309
18.1 GILEAD SCIENCES, INC. (2022) 309
18.1.1 COMPANY SNAPSHOT 309
18.1.2 REVENUE ANALYSIS 309
18.1.3 COMPANY SHARE ANALYSIS 310
18.1.4 PRODUCT PORTFOLIO 310
18.1.5 RECENT DEVELOPMENT 310
18.2 PFIZER INC. (2022) 311
18.2.1 COMPANY SNAPSHOT 311
18.2.2 REVENUE ANALYSIS 311
18.2.3 COMPANY SHARE ANALYSIS 312
18.2.4 PRODUCT PORTFOLIO 312
18.2.5 RECENT DEVELOPMENTS 312
18.3 SIGA TECHNOLOGIES (2022) 313
18.3.1 COMPANY SNAPSHOT 313
18.3.2 REVENUE ANALYSIS 313
18.3.3 COMPANY SHARE ANALYSIS 314
18.3.4 PRODUCT PORTFOLIO 314
18.3.5 RECENT DEVELOPMENT 314
18.4 GLAXOSMITHKLINE PLC. 315
18.4.1 COMPANY SNAPSHOT 315
18.4.2 REVENUE ANALYSIS 315
18.4.3 COMPANY SHARE ANALYSIS 316
18.4.4 PRODUCT PORTFOLIO 316
18.4.5 RECENT DEVELOPMENT 316
18.5 F. HOFFMANN-LA ROCHE LTD. (2022) 317
18.5.1 COMPANY SNAPSHOT 317
18.5.2 REVENUE ANALYSIS 317
18.5.3 COMPANY SHARE ANALYSIS 318
18.5.4 PRODUCT PORTFOLIO 318
18.5.5 RECENT DEVELOPMENT 318
18.6 ABBVIE INC. 319
18.6.1 COMPANY SNAPSHOT 319
18.6.2 REVENUE ANALYSIS 319
18.6.3 PRODUCT PORTFOLIO 320
18.6.4 RECENT DEVELOPMENT 320
18.7 AUROBINDO PHARMA (2022) 321
18.7.1 COMPANY SNAPSHOT 321
18.7.2 REVENUE ANALYSIS 321
18.7.3 PRODUCT PORTFOLIO 322
18.7.4 RECENT DEVELOPMENT 322
18.8 AVET PHARMACEUTICALS INC. 323
18.8.1 COMPANY SNAPSHOT 323
18.8.2 PRODUCT PORTFOLIO 323
18.8.3 RECENT DEVELOPMENT 323
18.9 BRISTOLL MYERS SQUIBB (2022) 324
18.9.1 COMPANY SNAPSHOT 324
18.9.2 REVENUE ANALYSIS 324
18.9.3 PRODUCT PORTFOLIO 325
18.9.4 RECENT DEVELOPMENT 325
18.10 BIOCRYST PHARMACEUTICALS, INC. (2022) 326
18.10.1 COMPANY SNAPSHOT 326
18.10.2 REVENUE ANALYSIS 326
18.10.3 PRODUCT PORTFOLIO 327
18.10.4 RECENT DEVELOPMENT 327
18.11 CIPLA INC. (2022) 328
18.11.1 COMPANY SNAPSHOT 328
18.11.2 REVENUE ANALYSIS 328
18.11.3 PRODUCT PORTFOLIO 329
18.11.4 RECENT DEVELOPMENT 329
18.12 DR. REDDY'S LABORATORIES LTD. (2022) 330
18.12.1 COMPANY SNAPSHOT 330
18.12.2 REVENUE ANALYSIS 330
18.12.3 PRODUCT PORTFOLIO 331
18.12.4 RECENT DEVELOPMENTS 331
18.13 EMERGENT (2022) 332
18.13.1 COMPANY SNAPSHOT 332
18.13.2 REVENUE ANALYSIS 332
18.13.3 PRODUCT PORTFOLIO 333
18.13.4 RECENT DEVELOPMENT 333
18.14 HETERO. 334
18.14.1 COMPANY SNAPSHOT 334
18.14.2 PRODUCT PORTFOLIO 334
18.14.3 RECENT DEVELOPMENT 334
18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022) 335
18.15.1 COMPANY SNAPSHOT 335
18.15.2 REVENUE ANALYSIS 335
18.15.3 PRODUCT PORTFOLIO 336
18.15.4 RECENT DEVELOPMENT 336
18.16 MACLEODS PHARMACEUTICALS LTD. 337
18.16.1 COMPANY SNAPSHOT 337
18.16.2 PRODUCT PORTFOLIO 337
18.16.3 RECENT DEVELOPMENT 337
18.17 MERCK & CO., INC, (2022) 338
18.17.1 COMPANY SNAPSHOT 338
18.17.2 REVENUE ANALYSIS 338
18.17.3 PRODUCT PORTFOLIO 339
18.17.4 RECENT DEVELOPMENT 339
18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022) 340
18.18.1 COMPANY SNAPSHOT 340
18.18.2 REVENUE ANALYSIS 340
18.18.3 PRODUCT PORTFOLIO 341
18.18.4 RECENT DEVELOPMENT 341
18.19 NAVINTA LLC. 342
18.19.1 COMPANY SNAPSHOT 342
18.19.2 PRODUCT PORTFOLIO 342
18.19.3 RECENT DEVELOPMENT 342
18.20 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022) 343
18.20.1 COMPANY SNAPSHOT 343
18.20.2 REVENUE ANALYSIS 343
18.20.3 PRODUCT PORTFOLIO 344
18.20.4 RECENT DEVELOPMENT 344
18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022) 345
18.21.1 COMPANY SNAPSHOT 345
18.21.2 REVENUE ANALYSIS 345
18.21.3 PRODUCT PORTFOLIO 346
18.21.4 RECENT DEVELOPMENT 346
18.22 ZYDUS PHARMACEUTICALS, INC. (2022) 347
18.22.1 COMPANY SNAPSHOT 347
18.22.2 REVENUE ANALYSIS 347
18.22.3 PRODUCT PORTFOLIO 348
18.22.4 RECENT DEVELOPMENTS 348
19 QUESTIONNAIRE 349
20 RELATED REPORTS 352
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security